Source: PR Newswire

Press Release: Sensorium : Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024

/PRNewswire/ -- Sensorium Therapeutics, a biotechnology company developing novel, first-in-class medicines to treat a variety of CNS diseases, announced it...

Read full article »
Sensorium's Competitors | Sensorium's News | Sensorium's Financials
Stay up-to-date with the latest news on Sensorium
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Alexandra Glucksmann's photo - President & CEO of Sensorium

President & CEO

Alexandra Glucksmann

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Sensorium